These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30231691)

  • 1. Analysis of Review Times for Recent 505(b)(2) Applications.
    Sakai S; DiMasi JA; Getz KA
    Ther Innov Regul Sci; 2017 Sep; 51(5):651-656. PubMed ID: 30231691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prescription Drug User Fee Act of 1992 and the new drug development process.
    Kaitin KI
    Am J Ther; 1997; 4(5-6):167-72. PubMed ID: 10423607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities.
    Feng C; Virparia R; Mui ET
    Ther Innov Regul Sci; 2021 Jul; 55(4):881-888. PubMed ID: 33913098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Look At United States Drug Development and Approval Times.
    DiMasi JA
    Am J Ther; 1996 Sep; 3(9):647-657. PubMed ID: 11862306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Acknowledgment Letters and Filing Communications.
    Camp JR; Fuhs JV; Beattie SD; Asay RL; Hoffman RD
    Ther Innov Regul Sci; 2021 May; 55(3):568-582. PubMed ID: 33492633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA advisory committees and the new drug approval process.
    Kaitin KI; Melville A; Morris B
    J Clin Pharmacol; 1989 Oct; 29(10):886-90. PubMed ID: 2592579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements.
    Freije I; Lamouche S; Tanguay M
    Ther Innov Regul Sci; 2020 Jan; 54(1):128-138. PubMed ID: 32008242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update to Drugs, Devices, and the FDA: How Recent Legislative Changes Have Impacted Approval of New Therapies.
    Van Norman GA
    JACC Basic Transl Sci; 2020 Aug; 5(8):831-839. PubMed ID: 32864509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prescription Drug User Fee Act: Cause for Concern?
    Gabay M
    Hosp Pharm; 2018 Apr; 53(2):88-89. PubMed ID: 29581600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approval times for new drugs: does the source of funding for FDA staff matter?
    Carpenter D; Chernew M; Smith DG; Fendrick AM
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-618-24. PubMed ID: 15506165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.